Navigation Links
SIGA Passes First Hurdle with Lassa Fever Antiviral ST-193

leverages its proprietary technologies through multiple strategic partners, including the National Institutes of Health and TransTech Pharma, Inc. For more information about SIGA, please visit SIGA's Web site at www.siga.com.

About the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID)

USAMRIID, located at Fort Detrick, Maryland, is the lead medical research laboratory for the U.S. Biological Defense Research Program, and plays a critical role in national defense and in infectious disease research. The Institute's mission is to conduct basic and applied research on biological threats resulting in medical solutions (such as vaccines, drugs and diagnostics) to protect the warfighter. USAMRIID is a subordinate laboratory of the U.S. Army Medical Research and Materiel Command.

The information contained in this press release does not necessarily reflect the position or policy of the U.S. government, and no official endorsement should be inferred.

Forward-looking Statements

This Press Release contains or implies certain "forward-looking statements'' within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding the safety or efficacy of potential products, the timelines for bringing such products to market and the availability of funding sources for continued development of such products. Forward-looking statements are based on management's estimates, assumptions and projections, and are subject to uncertainties, many of which are beyond the control of SIGA. Actual results may differ materially from those anticipated in any forward-looking statement. Factors that may cause such differences include the risks that (a) potential products that appear promising to SIGA or its collaborators cannot be shown to be efficacious or safe in subsequent pre-clinical or clinical trials, (b) SIGA or its collaborators will not obtain appropriate or necessary governmental approval
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Senate Passes Drug-Safety Reforms to Prevent Future Vioxx-type Disasters; House Urged to Act on Strong Drug Safety Bill
2. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
3. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
4. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
5. Ablynx Announces Interim Results of First Nanobody Phase I Study of ALX-0081 (ANTI-VWF)
6. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
7. Advanced Life Sciences to Host Conference Call to Discuss Data From Cethromycins First of Two Phase 3 Pneumonia Trials
8. First Phase II Short-Term Study on Dapagliflozin Shows Results on Safety, Tolerability and Glycemic Markers in Subjects With Type 2 Diabetes
9. Advanced Cell Technology Develops First Human Embryonic Stem Cell Line without Destroying an Embryo
10. First Demonstration of nanoImmunology: a Nanomaterials-based Therapeutic Approach to Treat Allergy
11. First single breast cancer study to show significant survival benefit for women switching from tamoxifen to Arimidex
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: SIGA Passes First Hurdle with Lassa Fever Antiviral
(Date:9/17/2014)... 2014  Rebiotix Inc. announced this morning that results of ... RBX2660 (microbiota suspension) will be presented in two posters and ... Philadelphia from October 8-12. ... session on Thursday, October 9, 2014: Poster: RBX2660 ... Interim Analysis of the PUNCH-CD Phase 2 Safety Study ...
(Date:9/17/2014)... 17, 2014  Bayer HealthCare will present data on ... th Annual Meeting, which takes place September 18-20 ... which will be shared through poster presentations, showcase Bayer,s ... Data will be presented in a scientific forum. ... in hemophilia A patients, Bayer is maintaining its commitment ...
(Date:9/17/2014)... September 17, 2014 According to ... Component (Sensor, Battery, Memory Device, Display, & Microprocessor/MCU), by ... Wellness), and by Geography - Global Forecast to 2020", ... market is expected to reach $56.50 Billion by 2020, ... 2020. Browse 235 market data Tables and ...
Breaking Medicine Technology:PUNCH CD Study Drug Targeting Recurrent C. difficile Infection to be Presented at IDWeek 2014 2PUNCH CD Study Drug Targeting Recurrent C. difficile Infection to be Presented at IDWeek 2014 3PUNCH CD Study Drug Targeting Recurrent C. difficile Infection to be Presented at IDWeek 2014 4Bayer to Present Data on Hemophilia Research at NHF in Washington, D.C. 2Bayer to Present Data on Hemophilia Research at NHF in Washington, D.C. 3Bayer to Present Data on Hemophilia Research at NHF in Washington, D.C. 4Medical Electronics Market Worth $56.50 Billion by 2020 2Medical Electronics Market Worth $56.50 Billion by 2020 3Medical Electronics Market Worth $56.50 Billion by 2020 4
... (Nasdaq: ENDP ) today announced that it will present ... 2011 at 3:45 p.m. ET.  Dr. Ivan Gergel executive vice president ... programs. The presentation will be webcast live and can ... investors section.   About Endo ...
... nation,s leading retail pharmacy, brings its "To Your Health" ... Texas. The program will provide free preventive health screenings ... through November as a way to help citizens determine ... a path to better health. (Logo: ...
Cached Medicine Technology:CVS/pharmacy Debuts the 'To Your Health' Program in Dallas and Fort Worth Texas, Bringing More Than 80 Free Health Screening Events to the Community 2CVS/pharmacy Debuts the 'To Your Health' Program in Dallas and Fort Worth Texas, Bringing More Than 80 Free Health Screening Events to the Community 3
(Date:9/18/2014)... Angeles, CA (September 18, 2014) Cardiovascular disease is ... cholesterol plays a major role in accelerating its ... a treatment to decrease cholesterol-carrying lipoproteins such as ... harmful. A new study, out today in the ... finds that rosuvastatin may be more effective among ...
(Date:9/18/2014)... 2014 On August 23, the ... with the Distinguished Service Award for his contributions to ... 2014 National Basketball Retired Players Association (NBRPA) Legends World ... the Chicago Bulls in 1977, Glenn would go on ... Knicks, the Atlanta Hawks, and the Milwaukee Bucks throughout ...
(Date:9/18/2014)... September 18, 2014 One Week Kitchens will ... the Bloomsburg Fair beginning this Saturday. Their display will be ... great example of the products and design services that are ... various countertops for fair-goers to see. This display won ‘Most ... earlier this year and really is something to see. ...
(Date:9/18/2014)... September 18, 2014 Demand for competency-based ... seek more efficient routes to job placement and employers ... not have come at a better time as the ... supply. , Working in collaboration with employers, career educators ... approach to CBE implementation and direct assessment ...
(Date:9/18/2014)... 2014 SpineFrontier is expanding its ... partners in Less Exposure Surgery Technology by hiring ... an extensive education curriculum and trained sales representatives ... in Organizational Leadership, and has educated and trained ... Bringing her to the team is a big ...
Breaking Medicine News(10 mins):Health News:The HearStrong Foundation Recognizes Mike “Stinger” Glenn with the Distinguished Service Award at the 2014 Legends World Sports Conference 2Health News:The HearStrong Foundation Recognizes Mike “Stinger” Glenn with the Distinguished Service Award at the 2014 Legends World Sports Conference 3Health News:One Week Kitchens Taking Display to Bloomsburg Fair 2Health News:Wonderlic Unites Employers, Career Educators and Competency-Based Education Experts to Help Narrow Skills Gap 2Health News:SpineFrontier Inc. Makes Bold Move to Expand Its Internal Training Team to Collaborate With The LESSociety’s Less Exposure Surgery® University To Educate Surgeons. 2
... has come out with a finding published in the journal ... substance like marijuana, alcohol, and cigarettes in solitude, tend to ... to have a harder time quitting, as opposed to those ... ,The results stem from a study spreading over ...
... genome is remarkably similar to that of humans' and may ... //University of Central Florida professor Cristina Calestani and several colleagues ... November issue of Science. ,Sea urchins are ... sea urchin has been used for many years as a ...
... reports success of rapid 3-D cell-growth technique that produces ... lab, it looks, contracts //and responds almost like natural ... goal of creating replacement parts for damaged human hearts, ... a spoonful of loose heart cells. ,This ...
... will do the rounds of rural areas as part of ... marginalized populations. // ,The government has released initial ... to set up mobile medical units in rural areas. ... been given under the National Rural Health Mission (NRHM) scheme ...
... Brain scans may help doctors predict schizophrenia, a mental disorder ... a new study. // ,Researchers at the University of ... a high risk of developing schizophrenia because two or more ... online edition of BBC News said. ,The researchers ...
... scheme 'Assistance for capacity Building', Ministry of Health ... maximum //of Rs. 1.50 crores or actual, whichever ... facilities of State Hospitals of towns/cities located on ... Department of Road Transport and Highways and Ministry ...
Cached Medicine News:Health News:Sea Urchin Genome Similar To Man And May Cure Diseases 2Health News:A New Rapid 3-D Cell-Growth Technique For Growing Heart Muscle 2Health News:A New Rapid 3-D Cell-Growth Technique For Growing Heart Muscle 3
1% tryptone, 0.5% yeast extract, 1.0% Sodium Chloride. 1.5% agararose...
Luria bertani broth: 1.0% Tryptone, 0.5% Yeast Extract, 1.0% Sodium Chloride....
Luria bertani broth: 1.0% Tryptone, 0.5% Yeast Extract, 1.0% Sodium Chloride....
Inoculum Broth with Calcium Chloride and Phytone....
Medicine Products: